Acrivon has developed its AP3 Interactome, a proprietary, computational analytics platform driven by Generative ...

Detailed price information for Zentalis Pharmaceuticals Inc (ZNTL-Q) from The Globe and Mail including charting and trades.

H.C. Wainwright lowered the firm’s price target on Acrivon Therapeutics (ACRV) to $19 from $22 and keeps a Buy rating on the shares. The firm ...

Schrödinger today announced that new preclinical data on SGR-3515 and SGR-4174 will be presented at the AACR Annual Meeting ...

Detailed price information for Zentalis Pharmaceuticals Inc (ZNTL-Q) from The Globe and Mail including charting and trades.

ACESOT-1051 trial evaluating WEE1 kinase inhibitor APR-1051 now enrolling patients in Cohort 5; open label safety and efficacy data expected H2 ...

DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE) has entered into a Material Transfer Agreement (MTA) with MD ...

We look forward to evaluating its potential in patients.” MRANK-106 is a novel, orally available dual inhibitor of WEE1 and YES1 kinases discovered using MindRank’s proprietary AI platforms. MRANK-106 ...

Based on extensive preclinical studies, MRANK-106 is differentiated from other WEE1 inhibitors in development by its: Dual targeting of WEE1 and YES1 kinases, providing synergistic anti-tumor effects ...

Improved safety window compared to single-target WEE1 inhibitors The Phase I clinical trial, set to launch in 2025, will evaluate the safety, tolerability, pharmacokinetics, and preliminary anti ...

Based on extensive preclinical studies, MRANK-106 is differentiated from other WEE1 inhibitors in development by its: Dual targeting of WEE1 and YES1 kinases, providing synergistic anti-tumor ...